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nTel.: +420 543 18Editorial — Special issue: Heart FailureHeart failureHeart failure is undoubtedly one of key issues in current
cardiology. Since basic pharmacological therapy and the only
non-pharmacological alternative, cardiac transplant, in the
1980s, comprehensive therapy for heart failure has changed
dramatically over the last two decades. We have prepared this
special issue of Cor et Vasa devoted to current trends in the
diagnosis andmanagement of heart failure. A total of 17 original
research articles include reviews such as comparison of the 2011
Czech Society of Cardiology guidelines and 2012 European
Society of Cardiology recommendations as well as an updated
overview of natriuretic peptides, novel biomarkers for heart
failure, and current options for inﬂuencing the pathophysiologic
mechanisms of cardiac remodeling. Also discussed are BNP
dynamics in patients admitted for acute heart failure and the
impact of inﬂammatory changes and viral infection on the
development of dilated cardiomyopathy. Six articles deal with
cardiac transplant, including the role of hemodynamic support
in transplant programs. Last but not least, attention is paid to
the discussed but unresolved issues of optimization in non-
responders to cardiac resynchronization therapy, already a
standard non-pharmacological approach to advanced heartolecules and studies in the pharmacological t
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2200; fax: +420 543 18 2205.failure. These are supplemented with presentation of novel
statistical methods applied to data from the AHEAD registry.
We would like to demonstrate that heart failure issues
constitute a modern, rapidly developing part of cardiology
with a promising future in both pharmacological (see exam-
ples of new molecules in Table 1) and non-pharmacological
therapy.Jiří Vítovecn
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.herapy of heart failure.
N Clinical
study
phase
Primary endpoint
600 2 Dyspnea improvement
70 2 Hemodynamic response
301 2 Change in NT-proBNP from baseline
to 12 weeks of treatment
2116 3 Composite endpoint
360 4 72-h urinary volume, change in
cystatin C
160 4 Daily net ﬂuid output
450 4 1-year mortality or rehospitalization
250 3 Dyspnea improvement
